MIRNAVASC

Role of microRNAs in vascular diseases

Coordinatore	CHARITE - UNIVERSITAETSMEDIZIN BERLIN    more  Organization address address: Chariteplatz 1 city: BERLIN postcode: 10117 contact info Nome: Eveline Cognome: Fräßdorf Email: send email Telefono: +49 30450576024 Fax: +49 30450576954
Nazionalità Coordinatore	Germany [DE]
Totale costo	162˙661 €
EC contributo	162˙661 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2009-IEF
Funding Scheme	MC-IEF
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-10-01   -   2013-11-19

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	CHARITE - UNIVERSITAETSMEDIZIN BERLIN  Organization address address: Chariteplatz 1 city: BERLIN postcode: 10117 contact info Nome: Eveline Cognome: Fräßdorf Email: send email Telefono: +49 30450576024 Fax: +49 30450576954	DE (BERLIN)	coordinator	162˙661.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Atherothrombosis still represents the major cause of death in developed countries. All forms of atheroma are characterized by a risk of arterial wall rupture leading to clinical complications. This involves medial and adventitial ruptures in abdominal aortic aneurysm (AAA) and intimal cap rupture in vulnerable atherosclerotic plaques. In both cases the rupture may result in the occlusion of an artery by the formation of a thrombus causing an acute event. Being able to predict who is at risk of an acute cardiovascular event is at present one of the major challenges of cardiovascular medicine. MicroRNAs (miRNAs) are small (typically 22 nt in size) regulatory RNA molecules that function to modulate the activity of specific mRNA targets and play important roles in a wide range of physiologic and pathologic processes. Recent studies have revealed that miRNAs are able to modulate different pathological process involved in atherotrombosis. Our working hypothesis is that the development of atherothrombosis is a chronic process that is associated with miRNA dysregulation, that is, altered miRNA expression profiles may be the cause of many of the abnormalities related to atherotrombosis. The aim of this project is to link miRNA dysregulation to pathophysiology of atherothrombosis, with the aim of characterizing novel biomarkers which could be used in the diagnostic, prognostic and therapeutic setting.'